Ocugen updates include an amended proxy with a 1:2 to 1:8 reverse split, OCU400 Phase 3 data due Q1 2027, positive OCU410 Phase 2 results, and $37.5M financing extending cash runway to Q1 2027.Ocugen announced an amended preliminary proxy statement for its June 11, 2026 annual meeting, proposing a reverse stock split of 1:2 to 1:8. It also reports updates on OCU400 Phase 3 topline data due Q1 2027, positive Phase 2 results for OCU410, and a $37.5 million financing extending the cash runway into Q1 2027.

NodeGuardian

2026-04-21 07:47:22

Abstract generation in progress

Ocugen has announced an amended preliminary proxy statement for its Annual Meeting on June 11, 2026, including a proposal for a reverse stock split ranging from 1:2 to 1:8. The company also provided updates on its clinical programs, with OCU400 Phase 3 topline data expected in Q1 2027 and positive Phase 2 results for OCU410. Recent financing activities, totaling $37.5 million, are projected to extend the cash runway into Q1 2027.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
287.67K Popularity
#
Gate13thAnniversaryLive
1.03M Popularity
#
BitcoinBouncesBack
156.96K Popularity
#
USIranTalksProgress
867.56K Popularity
#
HKUnveilsNewCryptoRules
272.47K Popularity

Sitemap

Reverse split 1:2–1:8; OCU400 Phase 3 topline expected Q1 2027 — Ocugen (OCGN)

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin